In the population where, hormonal options are contraindicated or not preferred by the patient, it is essential to explore evidence-based non-hormonal pharmacological interventions for treating vasomotor symptoms. The 2024 landscape of available treatments has expanded yet again, arming the providers with an even wider range of possibilities to help their patients. Fezolinetant, is the first NK3R antagonist developed for the purpose of treating hot flashes in menopausal women. NK3R antagonists provide a safe and effective treatment option for managing menopausal women with VMS.
Keyphrases
- polycystic ovary syndrome
- end stage renal disease
- physical activity
- ejection fraction
- newly diagnosed
- chronic kidney disease
- insulin resistance
- peritoneal dialysis
- case report
- prognostic factors
- sleep quality
- metabolic syndrome
- patient reported outcomes
- pregnant women
- pregnancy outcomes
- depressive symptoms
- breast cancer risk